| abstract |
The invention discloses the application of a model constructed based on PCD-related gene combination in preparing a product for predicting the prognosis of colon adenocarcinoma. A prognostic model was constructed using 14 PCD key genes differentially expressed in colorectal cancer including (SPTBN2, DNAJC2, DRD4, SH3GL3, FOXS1, GSTM1, ISYNA1, NOL3, GPR27, PPARGC1A, RAB36, SEZ6L2, SERPINE1 and TNNT1) as detection targets PCDSig, the model has good 1-year, 2-year, and 3-year clinical prognosis prediction ability. The model can better distinguish high-risk groups from low-risk groups, and high-risk and low-risk patients are immune infiltration, and the response to immunotherapy is similar to There are differences in drug target gene expression and chemotherapeutic drug sensitivity. Models can be used to screen the target beneficiary population, effectively guiding the clinical practice of precise and personalized treatment, avoiding excessive treatment and delaying the patient's condition. Based on the above model, a nomogram was developed to predict the 1-year, 3-year, and 5-year survival probability of patients, and the model was visualized, which provided conditions for clinicians to judge the prognosis of COAD patients. |